Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .
Efficacy of Intravenous Iron Sucrose in Hemodialysis Patients with Restless Legs Syndrome (RLS): A Randomized, Placebo-Controlled Study
Background Restless legs syndrome ( RLS ) is a common disorder in hemodialysis ( HD ) patients that causes sleep disturbances and diminished quality of life . Because iron deficiency has been implicated in the pathogenesis of RLS , we sought to investigate the effects of intravenous ( IV ) iron sucrose on symptoms of RLS in HD patients . Material / Methods The study was a r and omized , placebo-controlled study of 1000 mg iron sucrose versus normal saline as placebo . Patients were evaluated at baseline and 2 weeks after the last injection . The severity of RLS was assessed using the International RLS Study Group rating scale ( IRLS ) . Blood sample s were taken to measure iron parameters reflecting the iron status , including serum ferritin ( SF ) concentration , percentage transferrin saturation ( TSAT% ) and hemoglobin ( Hb ) , and other biochemical parameters as safety assessment s , including creatinine ( Cr ) , urea , intact parathyroid hormone ( iPTH ) , and the index of urea clearance ( Kt/V ) . Adverse events were monitored in all subjects during the period of infusion . Results After 2 weeks , IRLS scores decreased more in the IV-iron group ( −7.38±2.03 ) than in the placebo group ( −0.81±2.61 ) ( P=0.000 ) . Serum ferritin , TSAT , and hemoglobin increased more in the IV-iron group ( 227.63±77.64 μg/L ; 26.06±7.77 % ; 13.98±3.62g/L , respectively ) than in the placebo group ( SF , p=0.000 ; TSAT , p=0.000 ; Hb , p=0.000 , respectively ) . There were no significant differences between IV-iron and placebo groups in Cr , urea , iPTH , and Kt/V. No adverse effects were observed in the study . Conclusions IV iron sucrose is a safe and effective treatment for reducing RLS symptoms in HD patients over the short-term
Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .